Evan Lippman - 14 May 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: EVP, Business Development
Issuer ticker: TEVA
Reported as of: 14 May 2026
Net transaction value: -$1,482,367
SEC form: 4
Accepted by SEC: 18 May 2026, 16:02:42 UTC
Prior SEC filing: 06 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Evan Lippman

Key filing fact

Evan Lippman filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 18 May 2026.

Key facts

This page summarizes Evan Lippman's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 18 May 2026, 16:02.

Change

Previous filing in this sequence was filed on 06 Mar 2026.
Current net transaction value: -$1,482,367.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002062834 Primary reporting owner

Lippman Evan

Relationship: EVP, Business Development
Address: C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
Signature: /s/ Dov Bergwerk as attorney-in-fact for Evan Lippman
Signature date: 18 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +11,841
Change %
Price
Shares after: 11,841
Date: 14 May 2026
Ownership: Direct
Footnotes: F1, F2

TEVA transaction

Ordinary Shares

Sale

Transaction value: $204,467
Shares: -5,746
Change %: -49%
Price: $35.58
Shares after: 6,095
Date: 14 May 2026
Ownership: Direct
Footnotes: F1, F3, F4, F5

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +74,008
Change %: +1214%
Price
Shares after: 80,103
Date: 14 May 2026
Ownership: Direct
Footnotes: F1, F2

TEVA transaction

Ordinary Shares

Sale

Transaction value: $1,277,900
Shares: -35,912
Change %: -45%
Price: $35.58
Shares after: 44,191
Date: 14 May 2026
Ownership: Direct
Footnotes: F1, F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TEVA transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -11,841
Change %: -25%
Price: $0.000000^*
Shares after: 35,524
Date: 14 May 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 11,841
Exercise price
Footnotes: F1, F2, F6

TEVA transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -74,008
Change %: -50%
Price: $0.000000^*
Shares after: 74,008
Date: 14 May 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 74,008
Exercise price
Footnotes: F1, F2, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 7 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Footnote F3

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

Footnote F4

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

Footnote F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.38 to $35.685, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F6

Restricted share units were granted on May 14, 2025, with 11,841 vested on May 14, 2026, 11,841 vesting on each of May 14, 2027 and May 14, 2028, and 11,842 vesting on May 14, 2029.

Footnote F7

Restricted share units were granted on May 14, 2025, with 74,008 vested on May 14, 2026, and 37,004 vesting on each of May 14, 2027 and May 14, 2028.